犬肿瘤免疫治疗性抗体研究进展及方向

doi:10.16431/j.cnki.1671-7236.2025.05.045

摘要/Abstract

摘要： 肿瘤是犬类健康的重大威胁，尤其在10岁以上的老年犬中较为常见。鉴于宠物犬与人类共享相同的生活环境，拥有较高的基因同源性，对犬肿瘤的发生机制、进展过程及有效治疗方法的研究，不仅对犬类健康至关重要，也可为人类肿瘤的研究和治疗提供宝贵的模型和启示。在兽医临床上，常规治疗犬肿瘤的方法有手术切除、化疗及放疗，虽然有一定的疗效，但也伴随着不可忽视的副作用和局限性。免疫疗法自兴起以来，因其安全性高、效果好，给肿瘤的治疗带来了新的希望和思路。随着肿瘤免疫治疗的迅速发展，抗体疗法作为免疫治疗的一种形式不断取得新的突破。治疗性抗体因其高亲和力、高特异性，被用于治疗人类多种肿瘤。然而，相较于人类医学领域，兽医肿瘤学临床实践中抗体疗法的应用较为有限。笔者结合抗体疗法在人类肿瘤治疗中的应用，对当前治疗性抗体在犬类肿瘤研究中的最新进展及潜在研究方向进行了综述，旨在为犬肿瘤治疗及临床试验提供新的思路。

关键词: 犬肿瘤; 免疫治疗; 抗体

Abstract: Cancer has become a big threat to the health of canines,especially for those over the age of 10.Given the same living environment shared between dogs and humans,and high degree of genetic homology,research on the mechanisms of canine tumor occurrence,progression,and effective treatments is not only crucial for pet dogs,but also provides valuable models and insights for human cancer research.In veterinary clinic,the conventional treatment for canine tumors includes surgical resection,chemotherapy and radiotherapy.Although they have certain curative effects,some side effects and limitations accompanied cannot be ignored.While immunotherapy has brought new hope and perspectives to the treatment of cancer due to its high safety and efficacy.With its rapid development,antibody therapy is making new breakthroughs.And therapeutic antibodies are used to treat various human tumors for their high affinity and selectivity.However,compared to the field of human medicine,the application of antibody therapy in veterinary oncology clinical practice is relatively limited.Here after combined the application of antibody therapy in human tumor treatment,the latest progress and potential research directions of therapeutic antibodies in canine tumor research were reviewed,aiming to provide new ideas for research and clinical trials in canine tumor treatment.

Key words: canine tumor; immunotherapy; antibody

中图分类号:

S858.292

秦梦可, 李慧鑫, 韩慧, 孟庆大, 谢闪闪. 犬肿瘤免疫治疗性抗体研究进展及方向[J]. 中国畜牧兽医, 2025, 52(5): 2432-2441.

QIN Mengke, LI Huixin, HAN Hui, MENG Qingda, XIE Shanshan. Research Progress and Direction of Immunotherapeutic Antibodies for Canine Tumor[J]. China Animal Husbandry and Veterinary Medicine, 2025, 52(5): 2432-2441.

参考文献

[1] FERLAY J,COLOMBET M,SOERJOMATARAM I,et al.Cancer statistics for the year 2020:An overview[J]. International Journal of Cancer,2021,149(4)：778-789.
[2] REZENDES A.Fighting cancer in dogs.Morris animal foundation leads campaign to find cures[J].Journal of the American Veterinary Medical Association,2007,230(9):1287-1288.
[3] SCHIFFMAN J D,BREEN M.Comparative oncology:What dogs and other species can teach us about humans with cancer[J]. Philosophical Transactions of the Royal Society B:Biological Sciences, 2015,370(1673):20140231.
[4] ADAMS V J,EVANS K M,SAMPSON J,et al.Methods and mortality results of a health survey of purebred dogs in the UK[J]. The Journal of Small Animal Practice,2010,51(10):512-524.
[5] HARTLEY G,ELMSLIE R,DOW S,et al.Checkpoint molecule expression by B and T cell lymphomas in dogs[J].Veterinary and Comparative Oncology,2018,16(3):352-360.
[6] WILLMANN M,HADZIJUSUFOVIC E,HERMINE O,et al.Comparative oncology:The paradigmatic example of canine and human mast cell neoplasms[J].Veterinary and Comparative Oncology,2019,17(1):1-10.
[7] 邢续扬,王孝春,何伟.肿瘤免疫治疗及其药物研发进展[J]. 中国药科大学学报,2021,52(1):10-19.XING X Y,WANG X C,HE W.Advances in tumor immunotherapy and its drug development[J].Journal of China Pharmaceutical University,2021,52(1):10-19.(in Chinese)
[8] KÖHLER G,MILSTEIN C.Continuous cultures of fused cells secreting antibody of predefined specificity[J]. Nature,1975,256(5517):495-497.
[9] SCHRAMA D,REISFELD R A,BECKER J C.Antibody targeted drugs as cancer therapeutics[J]. Nature Reviews Drug Discovery,2006,5(2):147-159.
[10] SALLES G,BARRETT M,FOÀ R,et al.Rituximab in B-cell hematologic malignancies:A review of 20 years of clinical experience[J]. Advances in Therapy,2017,34(10):2232-2273.
[11] SCOTT A M,WOLCHOK J D,OLD L J.Antibody therapy of cancer[J]. Nature Reviews Cancer,2012,12(4):278-287.
[12] ZOU X L,LI X B,KE H,et al.Prognostic value of neoantigen load in immune checkpoint inhibitor therapy for cancer[J].Frontiers in Immunology,2021,12:689076.
[13] AI L,XU A,XU J.Roles of PD-1/PD-L1 pathway:Signaling,cancer,and beyond[J]. Advances in Experimental Medicine and Biology,2020,1248:33-59.
[14] KEIR M E,BUTTE M J,FREEMAN G J,et al.PD-1 and its ligands in tolerance and immunity[J]. Annual Review of Immunology,2008,26:677-704.
[15] LUKE J J,RUTKOWSKI P,QUEIROLO P,et al.Pembrolizumab versus placebo as adjuvant therapy in completely resected stageⅡB or ⅡC melanoma (KEYNOTE-716):A randomised,double-blind,phase 3 trial[J]. Lancet,2022,399(10336):1718-1729.
[16] PINARD C J,HOCKER S E,POON A C,et al.Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines[J].Veterinary Immunology and Immunopathology,2022,243:110367.
[17] ARESU L,MARCONATO L,MARTINI V,et al.Prognostic value of PD-L1,PD-1 and CD8A in canine diffuse large B-cell lymphoma detected by RNA scope[J].Veterinary Sciences,2021,8(7):120.
[18] MAEKAWA N,KONNAI S,TAKAGI S,et al.A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma[J]. Scientific Reports,2017,7(1):8951.
[19] MAEKAWA N,KONNAI S,NISHIMURA M,et al.PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma[J]. Nature Partner Journals Precision Oncology,2021,5(1):10.
[20] IGASE M,NEMOTO Y,ITAMOTO K,et al.A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs[J]. Scientific Reports,2020,10(1):18311.
[21] XU S,XIE J,WANG S,et al.Reversing stage Ⅲ oral adenocarcinoma in a dog treated with anti-canine PD-1 therapeutic antibody:A case report[J]. Frontiers in Veterinary Science,2023,10:1144869.
[22] CEKANOVA M,RATHORE K.Animal models and therapeutic molecular targets of cancer:Utility and limitations[J].Drug Design,Development and Therapy,2014,8:1911-1921.
[23] HOSSEN M M,MA Y,YIN Z,et al.Current understanding of CTLA-4:From mechanism to autoimmune diseases[J]. Frontiers in Immunology,2023,14:1198365.
[24] LINSLEY P S,BRADY W,URNES M,et al.CTLA-4 is a second receptor for the B cell activation antigen B7[J]. The Journal of Experimental Medicine,1991,174(3):561-569.
[25] WEBER J,MANDALA M,DEL VECCHIO M,et al.Adjuvant nivolumab versus ipilimumab in resected stage Ⅲ or Ⅳ melanoma[J]. The New England Journal of Medicine,2017,377(19):1824-1835.
[26] ARIYARATHNA H,THOMSON N A,ABERDEIN D,et al.Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4(CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumors[J]. Veterinary Immunology and Immunopathology,2020,230:110142.
[27] MARABLE J,RUIZ D,JAISWAL A K,et al.Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients[J]. Scientific Reports,2021,11(1):20763.
[28] KE X,JIA L,WANG J,et al.Transfection of B7-1 cDNA empowers antigen presentation of blood malignant cells for activation of anti-tumor T cells[J].Chinese Medical Journal,2003,116(1):78-84.
[29] SCARPA M,SCARPA M,CASTAGLIUOLO I,et al.CD80 down-regulation is associated to aberrant DNA methylation in non-inflammatory colon carcinogenesis[J].BMC Cancer,2016,16:388.
[30] TIRAPU I,HUARTE E,GUIDUCCI C,et al.Low surface expression of B7-1(CD80) is an immunoescape mechanism of colon carcinoma[J].Cancer Research,2006,66(4):2442-2450.
[31] LIU Y,ZHENG P.Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy[J].Trends in Pharmacological Sciences,2020,41(1):4-12.
[32] KWON B S,WEISSMAN S M.cDNA sequences of two inducible T-cell genes[J]. Proceedings of the National Academy of Sciences,1989,86(6):1963-1967.
[33] CHESTER C,SANMAMED M F,WANG J,et al.Immunotherapy targeting 4-1BB:Mechanistic rationale,clinical results,and future strategies[J]. Blood,2018,131(1):49-57.
[34] WANG Y T,JI W D,JIAO H M,et al.Targeting 4-1BB for tumor immunotherapy from bench to bedside[J]. Frontiers in Immunology,2022,13:975926.
[35] MELERO I,HERVAS-STUBBS S,GLENNIE M,et al.Immunostimulatory monoclonal antibodies for cancer therapy[J]. Nature Reviews Cancer,2007,7(2):95-106.
[36] BARTKOWIAK T,CURRAN M A.4-1BB agonists:Multi-potent potentiators of tumor immunity[J]. Frontiers in Oncology,2015,5:117.
[37] MENK A V,SCHARPING N E,RIVADENEIRA D B,et al.4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses[J]. The Journal of Experimental Medicine,2018,215(4):1091-1100.
[38] HOUOT R,GOLDSTEIN M J,KOHRT H E,et al.Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion[J]. Blood,2009,114(16):3431-3438.
[39] SEGAL N H,LOGAN T F,HODI F S,et al.Results from an integrated safety analysis of urelumab,an agonist anti-CD137 monoclonal antibody[J]. Clinical Cancer Research,2017,23(8):1929-1936.
[40] SEGAL N H,HE A R,DOI T,et al.Phase Ⅰ study of single-agent utomilumab (PF-05082566),a 4-1BB/CD137 agonist,in patients with advanced cancer[J]. Clinical Cancer Research,2018,24(8):1816-1823.
[41] CLAUS C,FERRARA-KOLLER C,KLEIN C.The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy[J]. mAbs,2023,15(1):2167189.
[42] LENS S M,TESSELAAR K,VAN OERS M H,et al.Control of lymphocyte function through CD27-CD70 interactions[J]. Seminars in Immunology,1998,10(6):491-499.
[43] LAW C L,GORDON K A,TOKI B E,et al.Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates[J]. Cancer Research,2006,66(4):2328-2337.
[44] RYAN M C,KOSTNER H,GORDON K A,et al.Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75[J]. British Journal of Cancer,2010,103(5):676-684.
[45] ROBERTS D J,FRANKLIN N A,KINGETER L M,et al.Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence,and reduced PD-1 expression of tumor infiltrating CD8⁺ T cells[J]. Journal of Immunology,2010,33(8):769-779.
[46] RAMAKRISHNA V,SUNDARAPANDIYAN K,ZHAO B,et al.Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab[J]. Journal for Immunotherapy of Cancer,2015,3(1):37.
[47] SAKANISHI T,YAGITA H.Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice[J]. Biochemical and Biophysical Research Communications,2010,393(4):829-835.
[48] SANBORN R E,PISHVAIAN M J,CALLAHAN M K,et al.Safety,tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1(nivolumab) in advanced solid tumors[J]. Journal for Immunotherapy of Cancer,2022,10(8):e005147.
[49] GUELEN L,FISCHMANN T O,WONG J,et al.Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890:A human CD27 activating antibody for cancer immunotherapy[J]. Journal for Immunotherapy of Cancer,2022,10(9):e005049.
[50] WILLOUGHBY J,GRIFFITHS J,TEWS I,et al.OX40:Structure and function-What questions remain?[J]. Molecular Immunology,2017,83:13-22.
[51] LINCH S N,MCNAMARA M J,REDMOND W L.OX40 agonists and combination immunotherapy:Putting the pedal to the metal[J]. Frontiers in Oncology,2015,5:34.
[52] HENDRIKS J,XIAO Y,ROSSEN J W,et al.During viral infection of the respiratory tract,CD27,4-1BB,and OX40 collectively determine formation of CD8⁺ memory T cells and their capacity for secondary expansion[J]. Journal of Immunotherapy,2005,175(3):1665-1676.
[53] CURTI B D,KOVACSOVICS-BANKOWSKI M,MORRIS N,et al.OX40 is a potent immune-stimulating target in late-stage cancer patients[J]. Cancer Research,2013,73(24):7189-7198.
[54] ROGERS P R,SONG J,GRAMAGLIA I,et al.OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells[J]. Immunity,2001,15(3):445-455.
[55] REDMOND W L,LINCH S N,KASIEWICZ M J.Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity[J]. Cancer Immunology Research,2014,2(2):142-153.
[56] GUO Z,WANG X,CHENG D,et al.PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer[J]. PLoS One,2014,9(2):e89350.
[57] CHEN L,FLIES D B.Molecular mechanisms of T cell co-stimulation and co-inhibition[J]. Nature Reviews Immunology,2013,13(4):227-242.
[58] RUIZ D,HAYNES C,MARABLE J,et al.Development of OX40 agonists for canine cancer immunotherapy[J]. iScience,2022,25(10):105158.
[59] THAKUR A,HUANG M,LUM L G.Bispecific antibody based therapeutics:Strengths and challenges[J]. Blood Reviews,2018,32(4):339-347.
[60] PRZEPIORKA D,KO C W,DEISSEROTH A,et al.FDA approval:Blinatumomab[J]. Clinical Cancer Research,2015,21(18):4035-4039.
[61] LI X,DING Y,ZI M,et al.CD19,from bench to bedside[J]. Immunology Letters,2017,183:86-95.
[62] WANG T,TANG Y,CAI J,et al.Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia:A single-arm,multicenter,phase Ⅱ trial[J]. Journal of Clinical Oncology,2023,41(9):1670-1683.
[63] HARAN K P,LOCKHART A,XIONG A,et al.Generation and validation of an antibody to canine CD19 for diagnostic and future therapeutic purposes[J]. Veterinary Pathology,2020,57(2):241-252.
[64] TONG C,ZHANG Y,LIU Y,et al.Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma[J]. Blood,2020，136(14):1632-1644.
[65] HORNA P,NOWAKOWSKI G,ENDELL J,et al.Comparative assessment of surface CD19 and CD20 expression on B-cell lymphomas from clinical biopsies:Implications for targeted therapies[J].Blood,2019，134:5345.
[66] WANG Z.ErbB receptors and cancer[J]. Methods in Molecular Biology,2017,1652：3-35.
[67] ZAHAVI D,WEINER L.Monoclonal antibodies in cancer therapy[J]. Antibodies,2020,9(3):34.
[68] SINGER J,WEICHSELBAUMER M,STOCKNER T,et al.Comparative oncology:ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting[J]. Molecular Immunology,2012,50(4):200-209.
[69] SINGER J,FAZEKAS J,WANG W,et al.Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients[J]. Molecular Cancer Therapeutics,2014,13(7):1777-1790.
[70] RABIA E,GARAMBOIS V,DHOMMÉE C,et al.Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer[J]. Frontiers in Immunology,2023,14:1168444.
[71] TATEYAMA N,SUZUKI H,OHISHI T,et al.Antitumor activity of an anti-EGFR/HER2 bispecific antibody in a mouse xenograft model of canine osteosarcoma[J]. Pharmaceutics,2022,14(11):2494.
[72] 王俊敏,仵晨雨,雷文涛,等.PD-1/PD-L1与CTLA-4抑制剂联合治疗非小细胞肺癌的研究进展[J].临床肺科杂志,2021,26(11):1751-1755.WANG J M,WU C Y,LEI W T,et al.Research progress of PD-1/PD-L1 combined with CTLA-4 inhibitors in the treatment of non-small cell lung cancer[J].Journal of Clinical Pulmonary Medicine,2021,26(11):1751-1755.(in Chinese)
[73] CURRAN M A,MONTALVO W,YAGITA H,et al.PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors[J]. Proceedings of the National Academy of Sciences,2010,107(9):4275-4280.
[74] WOLCHOK J D,CHIARION-SILENI V,GONZALEZ R,et al.Overall survival with combined nivolumab and ipilimumab in advanced melanoma[J]. The New England Journal of Medicine,2017,377(14):1345-1356.
[75] ZHAO B W,ZHANG F Y,WANG Y,et al.LAG3-PD1 or CTLA4-PD1 inhibition in advanced melanoma:Indirect cross comparisons of the CheckMate-067 and RELATIVITY-047 trials[J]. Cancers,2022,14(20):4975.
[76] WEBER J S,GIBNEY G,SULLIVAN R J,et al.Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064):An open-label,randomised,phase 2 trial[J]. The Lancet Oncology,2016,17(7):943-955.
[77] LONG G V,ATKINSON V,CEBON J S,et al.Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029):An open-label,phase 1b trial[J]. The Lancet Oncology,2017,18(9):1202-1210.
[78] PANG X,HUANG Z,ZHONG T,et al.Cadonilimab,a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity[J]. mAbs,2023,15(1):2180794.
[79] GAO X Y,XU N,LI Z Y,et al.Safety and antitumour activity of cadonilimab,an anti-PD-1/CTLA-4 bispecific antibody,for patients with advanced solid tumours (COMPASSION-03):A multicentre,open-label,phase 1b/2 trial[J].The Lancet Oncology,2023,24(10):1134-1146.